GlassScriptPhysician profile
Natalie Mccall
NPI 1073196572
$4,555.28
in general payments reported to CMS, 2019-2025
39 companies · $1,763 in 2025
The $1,763 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $435 · 2022: $178 · 2023: $1,023 · 2024: $1,157 · 2025: $1,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,942.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $616.25 | 2021-2025 | |
| Janssen Biotech, INC. | $582.75 | 2021-2025 | Rybrevant, Tecvayli, Carvykti |
| Merck Sharp & Dohme LLC | $400.52 | 2021-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $338.72 | 2021-2025 | Calquence, Imfinzi, Enhertu |
| Incyte Corporation | $228.78 | 2021-2025 | Jakafi, Zynyz, Monjuvi |
| Pfizer INC. | $227.83 | 2023-2025 | |
| Celgene Corporation | $203.66 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Abbvie INC. | $148.11 | 2025 | |
| Stemline Therapeutics INC. | $145.36 | 2023-2025 | Orserdu |
| Daiichi Sankyo INC. | $138.79 | 2023-2025 | Enhertu, Datroway |
| Exelixis INC. | $133.22 | 2021-2025 | Cabometyx |
| Eisai INC. | $130.68 | 2023-2025 | |
| Genzyme Corporation | $111.85 | 2023-2025 | |
| Glaxosmithkline, LLC. | $90.96 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Ipsen Biopharmaceuticals, INC | $84.35 | 2024-2025 | Somatuline Depot, Onivyde |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $84.21 | 2021-2025 | Xtandi, Vyloy, Padcev |
| Gilead Sciences, INC. | $81.70 | 2023-2025 | Trodelvy |
| Beigene USA, INC. | $81.29 | 2023-2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $77.12 | 2023-2025 | Xpovio |
| Array Biopharma INC | $76.21 | 2025 | Lorbrena, Braftovi, Mektovi |
| Taiho Oncology, INC. | $64.59 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $61.10 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $49.81 | 2024-2025 | |
| Seagen INC. | $44.11 | 2021-2023 | Tukysa, Adcetris |
| Genentech USA, INC. | $42.23 | 2023-2025 | Phesgo, Itovebi, Kadcyla |
| Bayer Healthcare Pharmaceuticals INC. | $37.25 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.00 | 2024 | Ninlaro |
| Amgen INC. | $26.92 | 2022 | |
| Servier Pharmaceuticals LLC | $23.34 | 2025 | |
| Emd Serono, INC. | $23.31 | 2024 | |
| Adc Therapeutics America, INC. | $21.97 | 2024 | |
| Morphosys, US INC. | $21.32 | 2021 | |
| Pharmacosmos Therapeutics INC. | $19.99 | 2024 | Monoferric |
| Acrotech Biopharma INC. | $19.88 | 2025 | Beleodaq |
| Rigel Pharmaceuticals, INC. | $18.11 | 2023 | Rezlidhia, Tavalisse |
| Mirati Therapeutics, INC. | $17.99 | 2023 | Krazati |
| Lilly USA, LLC | $17.95 | 2025 | Jaypirca, Verzenio |
| Pharmaessentia USA Corporation | $17.41 | 2023 | Besremi |
| Beone Medicines USA, INC. | $13.64 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Mccall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.